Optina Diagnostics and Diagnos Partner for Online Alzheimer's Disease Detection Platform

By: Tomas Ronolski - AllPennyStocks.com News

Wednesday, September 5, 2018

It's been over 30 years since the first histological evidence for retinal abnormalities in patients with Alzheimer's disease was first presented, but progress in the area has been slow. There are many challenges, including abnormalities that share characteristics with other diseases and conditions creating overlap. Still, the battle goes on to address Alzheimer's at the earliest possible opportunity, including Diagnos ( TSX-V:ADK)(OTCQB:DGNOF) and Optina Diagnostics saying on Wednesday that they have partnered to develop an online platform for early detection of the degenerative disease.
Per the accord, Brossard, Quebec-based Diagnos is providing Montreal-based Optina a telemedicine platform based on its CARA (Computer Assisted Retina Analysis) technology. Cleared for commercialization by Health Canada and the U.S. FDA, CARA is Diagnos's tele-ophthalmology platform that integrates with existing hardware and software and uses artificial intelligence to make standard retinal images sharper and easier to read. The technology is compatible with all known image formats and fundus cameras, while being securely accessible via the web.
Optina will use Diagnos cloud services to upload images generated by its hyperspectral cameras, processing the images to look for key retinal biomarkers in a bid to identify Alzheimer's disease. Furthermore, the images will be available for sharing with appropriate health care professionals.
Diagnos will realize revenue from the CARA cloud services use and believes that teaming with Optina will create added industry exposure. "This partnership will foster more collaboration with other biotech firms and attract new clients in need of a telemedicine platform.” said Yves-Stephane Couture, Vice President of Sales at Diagnos, in today's news release.
For its part, Optima sees the partnership as expediting the commercialization of their Alzheimer's diagnostic test, while providing an effective and efficient user experience.
Toronto-listed shares of ADK are flat at 6.5 cents Wednesday morning following the news.

Copyright © 2018 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.